1 / 8

Hepatocellular Carcinoma Drugs Market - Global Industry Insights, 2026

Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin.

RupeshD
Download Presentation

Hepatocellular Carcinoma Drugs Market - Global Industry Insights, 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatocellular Carcinoma Drugs Market GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2018- 2026 © Coherent market Insights. All Rights Reserved

  2. REPORT DESCRIPTION Hepatocellular Carcinoma Drugs Market – Overview Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy and targeted drug therapy. A majority of the HCC patients are diagnosed at the end-stage of liver dysfunction. Due to poor prognosis of the condition, mortality rate is approximately the same as the incidence rate. Therefore, early detection of the cancer is an important parameter to improve the survival of affected patients, thus aiding in growth of the global hepatocellular carcinoma drugs market. Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin. Click To Continue Reading on Hepatocellular Carcinoma Drugs Market © Coherent market Insights. All Rights Reserved

  3. REPORT DESCRIPTION Hepatocellular Carcinoma Drugs MarketTaxonomy: On the basis of drug class, global hepatocellular carcinoma drugs market is segmented into: PD-1/PD-L1 Inhibitors ● Nivolumab (Opdivo) ● Tyrosine Kinase Inhibitors ● Sorafenib (Nexavar) ● Regorafenib (Stivarga) ● On the basis of end user, the global hepatocellular carcinoma drugs market is segmented into: Hospital ● Clinics ● Cancer Rehabilitation Centers ● Ambulatory Surgical Centers ● Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1596 © Coherent market Insights. All Rights Reserved

  4. REPORT DESCRIPTION Hepatocellular Carcinoma Drugs Market: Key Players Major players involved in the global hepatocellular carcinoma drugs market include: Novartis Pharmaceuticals ● Bayer AG ● Merck & Co., Inc. ● Bristol-Myers Squibb Company ● AbbVie Inc. ● Johnson & Johnson ● Celgen Corporation ● Amgen Inc. ● Teva Pharmaceutical Industries Ltd. ● Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1596 © Coherent market Insights. All Rights Reserved

  5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

  6. ABOUT COHERENT MARKET INSIGHTS Industries we cater SECTOR COVERAGE Healthcare CLINICAL DIAGNOSTIC HEALTHCARE IT BIOTECHNOLOGY PHARMACEUTICAL MEDICAL IMAGING MEDICAL DEVICES Chemicals & Materials Speciality and Fine Chemicals Bulk Chemicals Advanced Materials Green Chemicals Polymers & Resins Food Ingredients Cosmetic Ingredients © Coherent market Insights. All Rights Reserved

  7. ABOUT COHERENT MARKET INSIGHTS KEY STATS RESEARCH SOLUTIONS GLOBAL REPORTS FEASIBILITY STUDIES 100+ Insights Published Per Year CUSTOMIZED SOLUTIONS COUNTRY ANALYSIS Consulting Projects Till Date 150+ CONSULT PROJECTS SURVEY RESEAR CH EXCEL FORECAST DATABASE 125+ COMPETITIVE ASSESSMENT Clients Worldwide Per Year 110+ TECHNOLOGY SNIPPETS Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

  8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved

More Related